Διεθνή Νέα

New EMA recommendations for the use of CORLENTOR/PROCORALAN

(21/11/2014)

Servier launches Cardiological, a mobile medical application to understand cardiovascular diseases

(03/7/2014)

Servier Research Group announces the death of President-Founder Dr. Jacques Servier

(16/4/2014)

European Medicines Agency recommends that PROTELOS®/OSSEOR® remain available with further restrictions

(21/2/2014)

Curie-Cancer and Servier continue a renewed partnership in cancer research

(30/1/2014)

PROTELOS / OSSEOR: European Committee for Pharmacovigilance Recommendation

(10/1/2014)

Servier's takeover bid of Egis proves successful

(08/11/2013)

Servier partners A*STAR to develop immunity-modulating drugs to combat cancer and autoimmune diseases

(19/09/2013)

Servier concludes a license agreement with SIMM for the development in China of lucitanib

(13/09/2013)

SERVIER CANADA announces the creation of a new Centre of Excellence in Clinical Research

(09/09/2013)

ISHR – Servier Research Fellowship

(06/08/2013)

The 2013 Servier Award in Microcirculation(06/08/2013)

Nerviano Medical Sciences and Servier announce a Collaboration and License Agreement for a Novel Anticancer Drug

(30/07/2013)

Galapagos delivers novel osteoarthritis molecules in alliance with Servier

(25/07/2013)

Servier Research Grant in Hypertension

(16/07/2013)

Pierre Delmas Prize 2013 winner

(16/07/2013)

Amgen and Servier announce product collaboration

(09/07/2013)

XOMA Transfers Perindopril Franchise Rights to Symplmed

(03/07/2013)

XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program for Gevokizumab

(25/06/2013)

miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier

(23/05/2013)

Afraxis, Inc. and Servier Announce a collaboration on ESP Platform for Drug Discovery in Central Nervous System Disorders

(30/04/2013)

Vernalis and Servier Extend Oncology Collaboration

(06/03/2013)

Achievement of new milestones in Galapagos alliances with Servier

(06/03/2013)

XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

(20/02/2013)

The UIP/Servier Research Fellowship 2013/2015 - Call for application

(04/01/2013)

Valdoxan® (agomelatine): Award of the Italian Prix Galien 2012

(03/12/2012)

XOMA announces Servier has initiated a proof-of-concept Gevokizumab study in patients with a history of acute coronary syndrome

(29/11/2012)

Professor Caroline Dive, University of Manchester, winner of the 2012 Pasteur-Weizmann/Servier Prize

(28/11/2012)

Servier Research Grant in Hypertension: call for application

(28/11/2012)

G.B. Morgagni Prizes 2012 Winners

(20/11/2012)

XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial

(20/11/2012)

NovAliX and Servier Collaborate in Early Discovery Research Program

(27/10/2012)

Information about Valdoxan for health care professionals

(10/10/2012)

Information about Valdoxan for patients

(10/10/2012)

Servier-Ruijin Talent Development and Scientific Exchanges

(08/10/2012)

Celebrating the 10th Anniversary of Servier Tianjin Pharmaceutical Company

(08/10/2012)

XOMA Initiates Safety and Efficacy Study of Gevokizumab in PatientXOMA Initiates Safety and Efficacy Study of Gevokizumab in Patients with Non-infectious Uveitis Currently Controlled by Systemic Treatments with Non-infectious Uveitis

(03/10/2012)

Servier concludes a collaboration and license agreement with EOS for its antitumor drug E-3810

(01/10/2012)

The Florey Institute of Neuroscience and Mental Health and Servier to collaborate on a Novel Target for Alzheimer’s Disease

(28/09/2012)

XOMA Announces Servier has Initiated Phase 3 Gevokizumab Trial in Patients with Behçet’s Uveitis

(27/09/2012)

Servier and MacroGenics Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

(20/09/2012)

Servier Announces Manufacturing Agreement with Boehringer Ingelheim

(03/08/2012)

The winner of the 2011 Servier/UIP (Union Internationale de Phlébologie) Research Fellowship is Doctor Győző SZOLNOKY

(19/07/2012)

Renewal and extension of the collaborative contract between Servier and Genepep for the development of chemical protein synthesis

(10/07/2012)

IOF-SERVIER Research Grant: the 2012 winner is Mark EDWARDS

(29/06/2012)

The European Medicines Agency confirms the positive benefit-risk balance of Vastarel* as add-on to first line therapy in the treatment of stable angina

(22/06/2012)